Evaluation of a Physical Activity Program for Pathological Gamblers in Treatment
Carregando...
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2013
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Citação
JOURNAL OF GAMBLING STUDIES, v.29, n.3, p.589-599, 2013
Resumo
It has been demonstrated that craving for gambling is associated with anxiety and depression in pathological gamblers. Exercise has been shown to reduce anxiety and depression, as well as positively influence abstinence rates in individuals with substance use disorders. In this study, we examined the impact of a physical activity program in 33 pathological gamblers. We also analyzed the association between craving and plasmatic levels of stress hormones (adrenocorticotropic hormone, cortisol, and prolactin). The program involved eight 50-min sessions. Craving was assessed 24 h before, immediately before, and immediately after each session, as well as on a weekly basis. Before and after the program, we evaluated gambling behavior, depressive symptoms, anxiety, and plasma levels of stress hormones. We identified a significant reduction in craving following each session and at the end of the program. There was improvement in anxiety, depressive symptoms, and gambling behavior. The post-session reduction in craving was accompanied by post-program reductions in craving and anxiety but not by a post-program reduction in depressive symptoms. The craving reduction was associated with a variation in prolactin levels but not with variations in levels of cortisol or adrenocorticotropic hormone.
Palavras-chave
Gambling, Addiction, Impulse control disorders, Physical activity
Referências
- American College of Sports Medicine (ACSM), 1991, GUID EX TEST PRESCR
- Angelo DL, 2009, REV BRAS PSIQUIATR, V31, P76, DOI 10.1590/S1516-44462009000100017
- APA, 1994, DIAGN STAT MAN MENT
- BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893
- BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561
- Blumenthal JA, 2007, PSYCHOSOM MED, V69, P587, DOI 10.1097/PSY.0b013e318148c19a
- Carter T, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-187
- Castro V., 2005, CANADIAN J PSYCHIAT, V50, P81
- Crockford DN, 1998, CAN J PSYCHIAT, V43, P43
- Dishman RK, 2006, OBESITY, V14, P345, DOI 10.1038/oby.2006.46
- Dunn AL, 2005, AM J PREV MED, V28, P1, DOI 10.1016/j.amepre.2004.09.003
- Flannery BA, 1999, ALCOHOL CLIN EXP RES, V23, P1289, DOI 10.1097/00000374-199908000-00001
- Ibáñez Angela, 2003, J Gambl Stud, V19, P11, DOI 10.1023/A:1021271029163
- Kiive E, 2004, PROG NEURO-PSYCHOPH, V28, P1007, DOI 10.1016/j.pnpbp.2004.05.035
- Krueger THC, 2005, NEUROPSYCHOBIOLOGY, V52, P206, DOI 10.1159/000089004
- LUGER A, 1987, NEW ENGL J MED, V316, P1309, DOI 10.1056/NEJM198705213162105
- Martinsen EW, 2008, NORD J PSYCHIAT, V62, P25, DOI 10.1080/08039480802315640
- MCNEIL JK, 1991, PSYCHOL AGING, V6, P487, DOI 10.1037//0882-7974.6.3.487
- Meyer G, 2004, PSYCHONEUROENDOCRINO, V29, P1272, DOI 10.1016/j.psyneuen.2004.03.005
- Meyer G, 2000, BIOL PSYCHIAT, V48, P948, DOI 10.1016/S0006-3223(00)00888-X
- Potenza M N, 2001, Semin Clin Neuropsychiatry, V6, P217, DOI 10.1053/scnp.2001.22929
- Potenza MN, 2002, J GEN INTERN MED, V17, P721, DOI 10.1046/j.1525-1497.2002.10812.x
- Ribeiro F. C. A., 2011, CURRENT NEUROPHARMAC, V9, P45
- Singh N. A., 2000, NUTR CLIN CARE, V3, P197, DOI 10.1046/j.1523-5408.2000.00052.x
- Tavares H., 1999, REV PSIQUIATR CLIN, V26, P179
- Tordeurs D, 2011, ENCEPHALE, V37, P345, DOI 10.1016/j.encep.2011.02.003
- Ussher MH, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002295.pub3
- Weinstock J., 2008, REV BRAS PSIQUIAT S1, V30, P3
- Weiss RD, 1997, AM J ADDICTION, V6, P224